Home › Non-Small Cell Lung Cancer › Ohio
Non-Small Cell Lung Cancer clinical trials in Ohio
123 studies for Non-Small Cell Lung Cancer are looking for participants at sites in Ohio.
Cities in Ohio
- Columbus57 studies
- Cleveland48 studies
- Cincinnati31 studies
- Akron24 studies
- Toledo15 studies
- Dayton13 studies
- Youngstown5 studies
- Zanesville4 studies
- Parma3 studies
- Newark3 studies
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Dayton Physician's Network, Dayton
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Nov 13, 2026 · NCT05920356A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center, Cleveland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07111520Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- University Hospitals Cleveland Medical Center, Cleveland
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07100080This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- University Hospitals Seidman Cancer Center at UH Avon Health Center, Avon
- University Hospitals Cleveland Medical Center, Cleveland
- University Hospitals Seidman Cancer Center at UH Mentor Health Center, Mentor
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06758401Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Aultman Health Foundation, Canton
- Miami Valley Hospital South, Centerville
- Ohio State University Comprehensive Cancer Center, Columbus
- and 5 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06498635Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Cleveland Clinic Akron General, Akron
- Strecker Cancer Center-Belpre, Belpre
- Aultman Health Foundation, Canton
- and 34 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04267848A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103), Cincinnati
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06345729Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Cleveland Clinic, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04886804A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
- Cleveland Clinic, Cleveland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06868485Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
- Local Institution - 0438, Sandusky
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07680790A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- University of Cincinnati Medical Center ( Site 0119), Cincinnati
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT06623422A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- The James Cancer Hospital and Solove Research Institute, Columbus
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07541170A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Local Institution - 0486, Centerville
- University of Cincinnati Medical Center, Cincinnati
- Local Institution - 0512, Zanesville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT06561386A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- University Hospitals Seidman Cancer Center at UH Avon Health Center, Avon
- Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
- Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
- and 5 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07144280Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- ProMedica Flower Hospital, Sylvania
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07388524A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Ohio State University, Columbus
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06793215A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Akron General Medical Center, Akron
- The Christ Hospital, Cincinnati
- University Hospitals Cleveland Medical Center, Cleveland
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07361497A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06465069Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Aultman Hospital, Canton
- Miami Valley Hospital South, Centerville
- Fairview Hospital, Cleveland
- and 4 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06890598Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial
- University Hospitals Seidman Cancer Center, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07746388Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05579366Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Indu and Raj Soin Medical Center, Beavercreek
- Strecker Cancer Center-Belpre, Belpre
- Saint Elizabeth Boardman Hospital, Boardman
- and 11 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06418204A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- The Ohio State University (OSU) Wexner Medical Center, Columbus
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06400472A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Miami Valley Hospital South, Centerville
- USO - Oncology Hematology Care, Cincinnati
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06119581Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
- The Jame Outpatient Care West Campus, Columbus
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07397338XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors
- Investigator Site, Canton
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07688577Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT03191149Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
- Gabrail Cancer & Research Center, Canton
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05856981A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
- UH Cleveland Medical Center, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07542704FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- The Christ Hospital Physicians - Mt. Auburn, Cincinnati
- Ohio State University CRS, Columbus
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06303505A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07293247A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- University Hospitals Cleveland Medical Center, Cleveland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06667908A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
- Cleveland Clinic, Taussig Cancer Institute, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06720987Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- Gabrail Cancer Center Research, Canton
- The Christ Hospital Cancer Center, Cincinnati
- University of Cincinnati Medical Center, Cincinnati
- and 5 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT06712316Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
- University of Cincinnati Medical Center, Cincinnati
- University Hospitals Cleveland Medical Center, Cleveland
RecruitingPhase 3
Ages 18 to 90 · All sexes · Updated Nov 2, 2026 · NCT06745908Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Ohio State University Hospitals, Columbus
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07185997Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Local Institution - 007-893-B, Cincinnati
- USOR - Oncology Hematology Care - Blue Ash, Cincinnati
- Local Institution - 007-893-C, Cincinnati
- and 5 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT04613596KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0015), Columbus
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT04165070KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
- Ohio State University Comprehensive Cancer Center ( Site 0015), Columbus
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT04165798Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- University Hospitals Cleveland, Cleveland
- The James Cancer Hospital and Solove Research Institute, Columbus
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT05098132From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.